These data suggest that targeting the p53/TIGAR axis may alleviate hyperglycemia-induced cardiomyopathy via a mechanism involving the hypoxic signaling pathway and reprogrammed cell metabolism (Figure 6D). Here, TP53 is linked to cardiomyopathy.